InChIKey	DUYJMQONPNNFPI-UHFFFAOYSA-N
Compound Name	Osimertinib
Canonical SMILES	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	11
Pfam Stratification	Cross-Family
Avg pChEMBL	7.29
Source	ChEMBL;BindingDB

DrugBank ID	DB09330
Drug Name	Osimertinib
CAS Number	1421373-65-0
Groups	approved investigational
ATC Codes	L01EB04
Description	Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression ...

---

Categories: Acids, Acyclic Acrylates Amides Amines Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Inhibitors BCRP/ABCG2 Substrates Cytochrome P-450 CYP1A2 Inducers Cytochrome P-450 CYP1A2 Inducers (strength unknown) Cytochrome P-450 CYP3A Inducers Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inducers Cytochrome P-450 CYP3A4 Inducers (strength unknown) Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (weak) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates (strength unknown) Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Enzyme Inhibitors Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors Heterocyclic Compounds, Fused-Ring Kinase Inhibitor Narrow Therapeutic Index Drugs P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Protein Kinase Inhibitors Tyrosine Kinase Inhibitors

---

Cross-references: BindingDB: 50029668 ChEBI: 90943 CHEMBL3353410 ChemSpider: 31042598 Drugs Product Database (DPD): 22731 PDB: YY3 PharmGKB: PA166131626 PubChem:71496458 PubChem:310265210 RxCUI: 1721560 Wikipedia: Osimertinib ZINC: ZINC000098023177